Evaluation of Bone Quality in Patients With Rheumatoid Arthritis Treated With Baricitinib: Single Centre, Mode of Action Study (BARE BONE)
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BAREBONE
- 07 Oct 2019 Planned primary completion date changed from 11 Sep 2019 to 11 Sep 2020.
- 07 Oct 2019 Status changed from active, no longer recruiting to recruiting.
- 17 Oct 2018 New trial record